Tech giants are making massive investments in artificial intelligence. CoreWeave and Meta have expanded their cloud capacity ...

Approval is based on 96-week data from 2 pivotal trials showing majority of EYLEA HD patients maintained their visual and anatomic improvements ...

A first-in-human clinical trial evaluating an investigational gene therapy targeting complement-mediated pathways in ...

Bayer simplifies access to innovative eye care in India, enabling more patients to benefit from Eylea 2mg: Our Bureau, Bengaluru Thursday, April 2, 2026, 16:15 Hrs [IST] Bayer is ...

MK-8748 combines direct Tie2 pathway activation with VEGF inhibition, targeting persistent vascular leakage and vessel ...

Executives from 4D Molecular Therapeutics (NASDAQ:FDMT) outlined the company’s gene therapy platform, clinical progress, and ...

Valitor is advancing VLTR-559 through IND-enabling activities. About the MVP Technology Valitor’s Multivalent Polymer (MVP) technology platform originated at U.C. Berkeley. The MVP platform is based ...

The FDA approved an extension of dosing intervals for Eylea HD in patients with diabetic macular edema and wet age-related ...

April 9 (Reuters) - CoreWeave said on Thursday it had entered into an expanded agreement to provide Meta Platforms with $21 billion in cloud capacity, as the social media giant scales its ...

Dry age-related macular degeneration is the most common type — it happens when small deposits form under the retina, causing cells in the eye’s macula to die off. There’s currently no cure, but ...

Windows App & On Device AI fuels Speechify's dramatic growth with professionals and the enterprise. Privacy-first voice technology runs entirely on-device, with Copilot+ PCs (NPU from AMD, Intel and ...

Marvell (MRVL) stock surged 13% after Nvidia's $2B investment and partnership announcement. BofA raises price target to $125 ...